Drug

Mesutoclax clinical trials

Also written ICP-248.

studies test it: 5
open now: 5
in phase 3: 2
first study started: 2023

Keep track of what changes. Save the mesutoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

ICP-248: 5

Combined with it in one product

ICP-248+Orelabrutinib: 1
ICP-248 +Rituximab: 1
ICP-248+Orelabrutinib+Rituximab: 1

Studies by the year they started

5 studies that test it; most in 2024 (2)

Studies that test mesutoclax, by start year
Year	Studies
2023	1
2024	2
2025	1
2026	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 2
Phase 3: 2

What it is tested for

Each study’s main condition, where its own words name it.

Lymphoma, Mantle-Cell: 2
Hematologic Neoplasms: 2
Leukemia, Myeloid, Acute: 1

Who runs them

Industry 5 · Other 0

Beijing InnoCare Pharma Tech Co., Ltd. (5)

Often tested with

Tested in the same studies.

Orelabrutinib (3) · Azacitidine (1) · Rituximab (1)

Studies

Open first, then newest update. How each study uses mesutoclax is read from its arms, and is right about nine times in ten.

Testing it · 5

Given in every arm · 1 — mesutoclax is usual care beside what is tested

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesRecruitingPhase 1InnoCare Pharma Inc.NCT06351527Written as ICP-248

Codes

What other systems call mesutoclax · ClinicalTrials.gg INT015136

UNII (FDA) 5WGC3F4X8KMESUTOCLAXOne source FDA
NCI Thesaurus C215084MesutoclaxOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	5WGC3F4X8K	MESUTOCLAX	One source FDA
NCI Thesaurus	C215084	Mesutoclax	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.